IBD
-
股价暴涨400%！IBD领域迎来新秀
Abivax是一家法国公司，员工数目大概是70人，目前现金只有1亿欧元左右，但由于每年亏损约2亿欧元，大概只能支撑到今年年底。 然而，在“弹尽粮绝”之际，一则消息“救活”了他。 2…
-
【Preclinical】A safer and more effective small-molecule regulator of miR-124 for IBD treatment 【Product for Licensing】
Project ID：BP-20240718-OR-77 Product Brief Summary More highlights Contact us…
-
Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
First! FDA approves new indication for Johnson & Johnson’s IL-23 antibody
Congratulations to Johnson & Johnson!
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
股价暴涨75%！礼来32亿美元加码自免领域
未来，国内IBD市场是否也有交易出现？药时代将持续关注
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
-
32亿美元！礼来收购Morphic公司，加强炎症性肠病（IBD）新药研发
热烈祝贺礼来和Morphic公司！该收购将凭借口服整合素疗法扩展礼来的免疫学管线
-
A long-acting anti-TL1A mAb with best-in-class potential
If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)
